Natco receives final approval for generic Azacitidine for injection for USA market

Natco Pharma is pleased to announce final approval of Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (FDA) for Azacitidine for Injection, 100mg per Vial, Single-Dose Vial, a generic version of Vidaza by Celgene Corporation.

June 27, 2017 / 09:28 IST

RECEIVES FINAL APPROVAL
FOR GENERIC AZACITIDINE FOR INJECTION (VIDAZA®) for USA market
Source : BSE

first published: Jun 27, 2017 09:28 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Natco receives final approval for generic Azacitidine for injection for USA market

Natco Pharma is pleased to announce final approval of Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (FDA) for Azacitidine for Injection, 100mg per Vial, Single-Dose Vial, a generic version of Vidaza by Celgene Corporation.

NP01